Prostanoid function and cardiovascular disease

Archives of Physiology and Biochemistry

Volumn 114, Issue 3, 2008, Pages 201-209

  Iñiguez, Miguel A ^a   Cacheiro Llaguno, Cristina ^a   Cuesta, Natalia ^a   Díaz Muñoz, Manuel D ^a   Fresno, Manuel ^a  

^a CSIC   (Spain)

Author keywords

Cardiovascular physiopathology; Cyclooxygenases; NSAIDs; Prostaglandins; Prostanoid receptors; Thromboxanes

Indexed keywords

PROSTAGLANDIN;

CARDIOVASCULAR DISEASE; HOMEOSTASIS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; HOMEOSTASIS; HUMANS; PROSTAGLANDINS;

MUS;

EID: 47549096441     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450802180882     Document Type: Review

References (88)

1. Alfranca A, Iniguez MA, Fresno M, Redondo JM. 2006. Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc Res 70(3):446-56.
2. Babaev VR, Ding L, Reese J, Morrow JD, Breyer MD, Dey SK, Fazio S, Linton MF. 2006. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 113(1):108-17.
3. Banfi, C, Colli S, Eligini S, Mussoni L, Tremoli E. 2002. Oxidized LDLs influence thrombotic response and cyclooxygenase 2. Prostaglandins Leukot Essent Fatty Acids 67(2-3):169-73.
4. Belton O, Fitzgerald D. 2003. Cyclooxygenase-2 inhibitors and atherosclerosis. J Am Coll Cardiol 41(10):1820-22.
5. Belton O, Fitzgerald DJ. 2003. Cyclooxygenase isoforms and atherosclerosis. Expert Rev Mol Med 2003:1-18.
6. Berger J, Moller DE. 2002. The mechanisms of action of PPARs. Annu Rev Med 53:409-35.
7. Blanco JC, Contursi C, Salkowski CA, DeWitt DL, Ozato K, Vogel SN. 2000. Interferon regulatory factor (IRF)- 1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J Exp Med 191(12):2131-44.
8. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343(21):1520-8 (2 pages following 1528).
9. Bunting S, Moncada S, Vane JR. 1983. The prostacyclin-thromboxane A2 balance: pathophysiological and therapeutic implications. Br Med Bull 39(3):271-6.
10. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. 2002. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105(15):1816-23.
11. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF. 2005. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 39(3):443-52.
12. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. 2006. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 99(3):132-40.
13. Cipollone F, Fazia M, Iezzi A, Ciabattoni G, Pini B, Cuccurullo C, Ucchino S, Spigonardo F, De Luca M, Prontera C, Chiarelli F, Cuccurullo F, Mezzetti A. 2004. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol 24(7):1259-65.
14. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. 2001. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104(8):921-7.
15. Coruzzi G, Venturi N, Spaggiari S. 2007. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed 78(2):96-110.
16. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. 2002. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99(21):13926-31.
17. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. 2002. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296(5567):539-41.
18. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA. 2006. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116(5):1391-9.
19. Dannhardt G, Kiefer W. 2001. Cyclooxygenase inhibitors - current status and future prospects. Eur J Med Chem 36(2):109-26.
20. Davidge ST. 2001. Prostaglandin H synthase and vascular function. Circ Res 89(8):650-60.
21. Diaz-Cazorla M, Perez-Sala D, Ros J, Jimenez W, Fresno M, Lamas S. 1999. Regulation of cyclooxygenase-2 expression in human mesangial cells - transcriptional inhibition by IL-13. Eur J Biochem 260(1):268-74.
22. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, Fitzgerald GA. 2004. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306(5703):1954-7.
23. FitzGerald GA. 2003. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2(11):879-90.
24. FitzGerald GA, Austin S, Egan K, Cheng Y, Pratico D. 2000. Cyclo-oxygenase products and atherothrombosis. Ann Med 32 Suppl 1:21-6.
25. FitzGerald GA, Patrono C. 2001. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345(6):433-42.
26. Flavahan NA. 2007. Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci 28(3):106-10.
27. Fosslien E. 2005. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann Clin Lab Sci 35(4):347-85.
28. Francois H, Athirakul K, Howell D, Dash R, Mao L, Kim HS, Rockman HA, FitzGerald GA, Koller BH, Coffman TM. 2005. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2(3):201-7.
29. Fuse I, Higuchi W, Aizawa Y. 2000. Pathogenesis of a bleeding disorder characterized by platelet unresponsiveness to thromboxane A2. Semin Thromb Hemost 26(1):43-5.
30. Grau R, Iniguez MA, Fresno M. 2004. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism. Cancer Res 64(15):5162-71.
31. Hansson GK, Libby P. 2006. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6(7):508-19.
32. Hata AN, Breyer RM. 2004. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103(2):147-66.
33. Helliwell RJ, Adams LF, Mitchell MD. 2004. Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids 70(2):101-13.
34. Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. 1994. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 94(4):1662-7.
35. Ide T, Egan K, Bell-Parikh LC, FitzGerald GA. 2003. Activation of nuclear receptors by prostaglandins. Thromb Res 110(5-6):311-15.
36. Iniguez MA, Martinez-Martinez S, Punzon C, Redondo JM, Fresno M. 2000. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 275(31):23627-35.
37. Iniguez MA, Punzon C, Fresno M. 1999. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 163(1):111-19.
38. Iniguez MA, Rodriguez A, Volpert OV, Fresno M, Redondo JM. 2003. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 9(2):73-8.
39. Kabashima K, Narumiya S. 2003. The DP receptor, allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids 69(2-3):187-94.
40. Kanaoka Y, Urade Y. 2003. Hematopoietic prostaglandin D synthase. Prostaglandins Leukot Essent Fatty Acids 69(2-3):163-7.
41. Karim S, Habib A, Levy-Toledano S, Maclouf J. 1996. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 271(20):12042-8.
42. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. 2006. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332(7553):1302-8.
43. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S. 2004. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114(6):784-94.
44. Kujubu DA, Herschman HR. 1992. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 267(12):7991-4.
45. Lopez JA, Armstrong ML, Harrison DG, Piegors DJ, Heistad DD. 1989. Vascular responses to leukocyte products in atherosclerotic primates. Circ Res 65(4):1078-86.
46. Martinez-Gonzalez J, Badimon L. 2007. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des 13(22):2215-27.
47. McGettigan P, Henry D. 2006. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. Jama 296(13):1633-44.
48. Morita I. 2002. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 68-69:165-75.
49. Murakami M, Kambe T, Shimbara S, Kudo I. 1999. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J Biol Chem 274(5):3103-15.
50. Murakami M, Nakashima K, Kamei D, Masuda S, Ishikawa Y, Ishii T, Ohmiya Y, Watanabe K, Kudo I. 2003. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 278(39):37937-47.
51. Murakami M, Nakatani Y, Tanioka T, Kudo I. 2002. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 68/69:383-99.
52. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S. 1997. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388(6643):678-82.
53. Niiro H, Otsuka T, Izuhara K, Yamaoka K, Ohshima K, Tanabe T, Hara S, Nemoto Y, Tanaka Y, Nakashima H, Niho Y. 1997. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood 89(5):1621-8.
54. Norata GD, Callegari E, Inoue H, Catapano AL. 2004. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol 24(5):871-7.
55. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. 2001. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 98(6):3358-63.
56. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. 2002. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360(9339):1071-3.
57. Reiss AB, Edelman SD. 2006. Recent insights into the role of prostanoids in atherosclerotic vascular disease. Curr Vasc Pharmacol 4(4):395-408.
58. Rocca B, Loeb AL, Strauss JF, 3rd, Vezza R, Habib A, Li H, FitzGerald GA. 2000. Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nat Med 6(2):219-21.
59. Ross R. 1999. Atherosclerosis - an inflammatory disease. N Engl J Med 340(2):115-26.
60. Rostom A, Muir K, Dube C, Jolicoeur E, Boucher M, Joyce J, Tugwell P, Wells GW. 2007. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 5(7):818-28, 828 e1-5; quiz 768.
61. Rudic RD, Brinster D, Cheng Y, Fries S, Song WL, Austin S, Coffman TM, FitzGerald GA. 2005. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 96(12):1240-7.
62. Samuelsson B, Morgenstern R, Jakobsson PJ. 2007. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59(3):207-24.
63. Scher JU, Pillinger MH. 2005. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol 114(2):100-9.
64. Simmons DL, Botting RM, Hla T. 2004. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56(3):387-437.
65. Smith WL, DeWitt DL, Garavito RM. 2000. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145-82.
66. Smyth EM, FitzGerald GA. 2002. Human prostacyclin receptor. Vitam Horm 65:149-65.
67. Straus DS, Glass CK. 2001. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21(3):185-210.
68. Subbaramaiah K, Dannenberg AJ. 2003. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24(2):96-102.
69. Tanabe T, Tohnai N. 2002. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 68/69:95-114.
70. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. 2000. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275(42):32775-82.
71. Tegeder I, Pfeilschifter J, Geisslinger G. 2001. Cyclooxygenase- independent actions of cyclooxygenase inhibitors. Faseb J 15(12):2057-72.
72. Thomas DW, Mannon RB, Mannon PJ, Latour A, Oliver JA, Hoffman M, Smithies O, Koller BH, Coffman TM. 1998. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 102(11):1994-2001.
73. Topper JN, Cai J, Falb D, Gimbrone MA, Jr. 1996. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93(19):10417-22.
74. Tsuboi K, Sugimoto Y, Ichikawa A. 2002. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 68/69:535-56.
75. Ueno N, Takegoshi Y, Kamei D, Kudo I, Murakami M. 2005. Coupling between cyclooxygenases and terminal prostanoid synthases. Biochem Biophys Res Commun 338(1):70-6.
76. Urade Y, Hayaishi O. 2000. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 1482(1-2):259-71.
77. Vane JR. 2002. Biomedicine. Back to an aspirin a day? Science 296(5567):474-5.
78. Vila L. 2004. Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med Res Rev 24(4):399-424.
79. Wang, LH, Kulmacz RJ. 2002. Thromboxane synthase: structure and function of protein and gene. Prostaglandins Other Lipid Mediat 68/69:409-22.
80. Wang M, Zukas AM, Hui Y, Ricciotti E, Pure E, FitzGerald GA. 2006. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 103(39):14507-12.
81. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. 1999. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96(13):7563-8.
82. Warner TD, Mitchell JA. 2004. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. Faseb J 18(7):790-804.
83. Watanabe K. 2002. Prostaglandin F synthase. Prostaglandins Other Lipid Mediat 68/69:401-7.
84. Williams CS, Mann M, DuBois RN. 1999. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18(55):7908-16.
85. Wu KK, Liou JY. 2005. Cellular and molecular biology of prostacyclin synthase. Biochem Biophys Res Commun.
86. Yamada M, Numaguchi Y, Okumura K, Harada M, Naruse K, Matsui H, Ito T, Hayakawa T. 2002. Prostacyclin synthase gene transfer modulates cyclooxygenase-2-derived prostanoid synthesis and inhibits neointimal formation in rat balloon-injured arteries. Arterioscler Thromb Vasc Biol 22(2):256-62.
87. Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S, Takeda J, Kinoshita T, Okabe M, Tanabe T. 2002. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 106(18):2397-403.
88. Yu Y, Cheng Y, Fan J, Chen XS, Klein-Szanto A, Fitzgerald GA, Funk CD. 2005. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J Clin Invest 115(4):986-95.